3970-66-9

Usage

Uses

Used in Pharmaceutical Industry:
1-BENZYL-4-METHYLPIPERIDIN-4-OL is used as a potent analgesic for the treatment of severe pain. It is particularly effective in managing conditions that require strong pain relief, such as postoperative pain, chronic pain, and pain associated with terminal illnesses. 1-BENZYL-4-METHYLPIPERIDIN-4-OL's high affinity for opioid receptors allows it to provide rapid and effective pain control.
Used in Pain Management:
1-BENZYL-4-METHYLPIPERIDIN-4-OL is used as a pain management tool in various medical settings, including hospitals, clinics, and palliative care facilities. Its ability to provide strong analgesia makes it a valuable asset in the management of acute and chronic pain conditions, improving the quality of life for patients suffering from severe pain.
Used in Research and Development:
1-BENZYL-4-METHYLPIPERIDIN-4-OL is also utilized in scientific research and drug development, particularly in the field of opioid pharmacology. Researchers study its mechanism of action, potential side effects, and interactions with other drugs to develop safer and more effective pain management therapies.

Upstream product

• 19867-34-6 N-benzyl-1-oxa-6-azaspiro[2,5]-octane 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 75-16-1 methylmagnesium bromide 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 155928-37-3 1-benzyl-4-acetylamino-4-methylpiperidine 
• 160133-26-6 1-benzyl-4-methyl-4-phenyl piperidine 
• 324002-53-1 N-benzyl-4-(4-chlorophenyl)-4-methylpiperidine 
• 710978-27-1 1-benzyl-4-isopropylcarboxamido-4-methylpiperidine 
• 3970-68-1 4-methylpiperidin-4-ol 
• 1093063-92-3 1-benzyl-4-(4-bromo-phenyl)-4-methyl-piperidine 
• 32018-56-7 1-benzyl-4-methyl-1 ,2,3,6-tetrahydropyridine 
• 1257301-27-1 1-benzyl-4-fluoro-4-methylpiperidine 
• 1186220-76-7 4-amino-N-(1-(3-(4-[¹⁸F]fluorophenoxy)propyl)-4-methylpiperidin-4-yl)-2-methoxybenzamide 
• 1186220-75-6 tert-butyl 4-(1-(3-(4-[¹⁸F]fluorophenoxy)propyl)-4-methylpiperidin-4-ylcarbamoyl)-3-methoxyphenylcarbamate 
• 155928-28-2 4-amino-N-[1-(3-(4-fluorophenoxy)propyl)-4-methylpiperidin-4-yl]-2-methoxy-benzamide 
• 1186220-74-5 tert-butyl 4-(1-(3-(4-fluorophenoxy)propyl)-4-methylpiperidin-4-ylcarbamoyl)-3-methoxyphenylcarbamate 
• 1186220-73-4 tert-butyl 3-methoxy-4-(4-methylpiperidin-4-ylcarbamoyl)phenylcarbamate 
• 1186220-72-3 tert-butyl 4-(1-benzyl-4-methylpiperidin-4-ylcarbamoyl)-3-methoxyphenylcarbamate 

Relevant academic research and scientific papers

CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS

The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.

Deoxygenative Borylation of Secondary and Tertiary Alcohols

Two different approaches for the deoxygenative radical borylation of secondary and tertiary alcohols are presented. These transformations either proceed through a metal-free silyl-radical-mediated pathway or utilize visible-light photoredox catalysis. Readily available xanthates or methyl oxalates are used as radical precursors. The reactions show broad substrate scope and high functional-group tolerance, and are conducted under mild and practical conditions.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 9936396.1

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention al

(3R)-3-Amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides and 3-amino-N-(4-aryltetrahydropyran-4-yl)butanamides were synthesized and evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors. Derivatives incorporating the 6-substituted benzothiazole group showed highly potent DPP-IV inhibitory activity. Oral administration of (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide (12u) reduced blood glucose excursion in an oral glucose tolerance test.

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) or a salt thereof are provided: (I) wherein R4, R5, R6, Q and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic

2-CYANOPYRROLIDINECARBOXAMIDE COMPOUND

A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X1 and X2 each is independently lower alkylene; X3 is =CH2, =CHF or =CF2; R1 is substituent, R2 and R3 each is independently H or lower alkyl; n is 0, 1, 2, 3 or 4.] having the activity inhibiting DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.